WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Richard Pops Biography and Net Worth

Director of Neurocrine Biosciences

Pops has served as a member of Acceleron’s board of directors since 2004. Since 2009,Pops has served as Chief Executive Officer and Chairman of the board of Alkermes.From 2007 to 2009 he served as the Chairman of the board of Alkermes, and from 1991 through 2007 he served as the Chief Executive Officer of Alkermes.

Pops also serves on the board of directors of Neurocrine Biosciences, Inc., Epizyme Inc., the Biotechnology Industry Organization and Pharmaceutical Researcher and Manufacturers of America.He has previously served on the board of directors of Sirtris Pharmaceuticals from 2004 to 2008, and CombinatoRx, Inc. from 2001 to 2009.

Pops also served on the board of directors of Reliant Pharmaceuticals, a privately held pharmaceutical company purchased by GlaxoSmithKline in 2007, and on the advisory board of Polaris Venture Partners.He was a member of the Harvard Medical School Board of Fellows from 2002 through June 2012.Pops received a BA in economics from Stanford University.

What is Richard F. Pops' net worth?: The estimated net worth of Richard F. Pops is at least $4.00 million as of March 8th, 2024. Mr. Pops owns 29,512 shares of Neurocrine Biosciences stock worth more than $3,996,515 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Pops may own. Learn More about Richard F. Pops' net worth.
How do I contact Richard F. Pops?: The corporate mailing address for Mr. Pops and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Richard F. Pops' contact information.
Has Richard F. Pops been buying or selling shares of Neurocrine Biosciences?: Richard F. Pops has not been actively trading shares of Neurocrine Biosciences in the last ninety days. Most recently, Richard F. Pops sold 100 shares of the business's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $140.00, for a transaction totalling $14,000.00. Following the completion of the sale, the director now directly owns 29,512 shares of the company's stock, valued at $4,131,680. Learn More on Richard F. Pops' trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 44 times. They sold a total of 542,972 shares worth more than $74,251,850.99. The most recent insider tranaction occured on December, 17th when insider Ingrid Delaet sold 1,091 shares worth more than $147,285.00. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 12/17/2024.

Richard F. Pops Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Sell	1,700	$140.05	$238,085.00	29,512
2/20/2024	Sell	15,000	$132.47	$1,987,050.00	29,512
5/9/2022	Sell	15,000	$76.30	$1,144,500.00	29,512
11/26/2018	Sell	4,124	$91.37	$376,809.88	29,512
11/12/2018	Sell	4,123	$103.30	$425,905.90	33,636
10/29/2018	Sell	5,500	$107.13	$589,215.00	37,759
5/25/2016	Sell	15,000	$46.72	$700,800.00	15,464

Richard F. Pops Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $135.42

$134.12

$137.01

50 Day Range

MA: $123.99

$115.08

$136.69

2 Week Range

Now: $135.42

$110.95

$157.98

Volume

2,265,589 shs

Average Volume

884,102 shs

Market Capitalization

$13.71 billion

P/E Ratio

36.31

Dividend Yield

N/A

Beta

0.34